Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined the human immune response to natural EBOV infection and identified mAbs with exceptionally potent panebolavirus neutralizing activity and protective efficacy against three virulent ebolaviruses. These mAbs recognize an inter-protomer epitope in the GP fusion loop, a critical and conserved element of the viral membrane fusion machinery, and neutralize viral entry by targeting a proteolytically primed, fusion-competent GP intermediate (GP CL ) generated in host cell endosomes. Only a few somatic hypermutations are required for broad antiviral activity, and germline-approximating variants display enhanced GP CL recognition, suggesting that such antibodies could be elicited more efficiently with suitably optimized GP immunogens. Our findings inform the development of both broadly effective immunotherapeutics and vaccines against filoviruses.
INTRODUCTION
Viruses of the family Filoviridae (filoviruses) cause outbreaks of a lethal disease for which no Food and Drug Administration (FDA)-approved treatments or vaccines are available. The unprecedented 2013-2016 Ebola virus (EBOV) epidemic in Western Africa highlighted the potential of these agents to cause health emergencies of international scope and has accelerated the development of countermeasures (de La Vega et al., 2015; Kuhn et al., 2014) . At the height of this epidemic, several earlystage therapeutics and vaccines were evaluated under compassionate-use protocols (Wong and Kobinger, 2015) . Arguably the most successful of these is ZMapp, an immunotherapeutic comprising three mouse/human chimeric monoclonal antibodies (mAbs), c2G4, c4G7, and c13C6, which target the glycoprotein (GP) spikes on the surface of EBOV virions. ZMapp was highly effective at reversing advanced EBOV disease (EVD) in non-human primates (NHPs) and provided initial evidence of efficacy in a phase II clinical trial (Davey et al., 2016; Qiu et al., 2014) . Despite its promise, ZMapp suffers a key limitation. It lacks activity against other filoviruses associated with human disease, including Bundibugyo virus (BDBV), Sudan virus (SUDV), and Marburg virus (MARV), because its component mAbs do not recognize and neutralize these divergent GPs (Murin et al., 2014) . The public health threat represented by BDBV and SUDV, which caused z40% of all ebolavirus infections prior to 2013 (Burk et al., 2016) , and by newly emerging or engineered ebolaviruses, demands an urgent response.
Given the scientific and logistical hurdles inherent in developing a separate mAb therapeutic for each filovirus, recent work has focused on the development of broadly protective immunotherapies. Frei et al. (2016) combined known EBOV and SUDV GP-specific neutralizing antibodies (NAbs) KZ52 and a humanized variant of 16F6, respectively, to generate bispecific antibodies that protected against both viruses in mice. More recently, bispecific antibodies combining two broadly reactive but non-neutralizing mAbs targeting virus:host receptor interactions were shown to neutralize all known ebolaviruses through a ''Trojan horse'' mechanism and to protect mice challenged with EBOV or SUDV . The presence of cross-reactive and cross-neutralizing antibodies in natural antibody repertoires following monospecific ebolavirus infection or immunization has also been noted (Bornholdt et al., 2016b; Macneil et al., 2011; Natesan et al., 2016) , and antibody discovery efforts have yielded cross-neutralizing mAbs with increased protective breadth Furuyama et al., 2016; Howell et al., 2016; Keck et al., 2015) . To date, however, only a single canonical IgG with true pan-ebolavirus neutralizing activity-the mouse mAb 6D6-has been reported (Furuyama et al., 2016) . Moreover, no natural or engineered antibody has yet been shown to protect animals against EBOV, BDBV, and SUDV (Burk et al., 2016) .
Here, we sought to perform a systematic analysis of the breadth of the anti-ebolavirus neutralizing mAb response in humans. Accordingly, we screened our recently published library of 349 human mAbs isolated from a survivor of the recent West African EBOV outbreak (Bornholdt et al., 2016b) for broad neutralizers. We identified two mAbs that could potently neutralize all five ebolaviruses and confer post-exposure protection against EBOV, BDBV, and SUDV in animal challenge models. Follow-up studies indicated that these mAbs recognize a hitherto unknown GP epitope that encompasses membraneseeking residues in the internal fusion loop and mediate neutralization by targeting a proteolytically cleaved GP intermediate in the endocytic pathway. Together, our findings inform the development of pan-ebolavirus immunotherapeutics and the design of filovirus vaccines tailored to elicit highly potent cross-protective antibodies.
RESULTS

Identification of Cross-Reactive and CrossNeutralizing mAbs
To identify broadly reactive mAbs in the EVD survivor library, we screened recombinant VSV (rVSV) particles displaying prototypic GPs from EBOV, BDBV, and SUDV by ELISA. 72% of the mAbs recognized BDBV GP, whereas only 11% cross-reacted with SUDV GP (Figure S1A) , consistent with the amino acid sequence conservation among these GPs. 37 of 349 mAbs reacted with all three GPs by ELISA (Figure S1B) . Within this subset, 16 mAbs belonged to the glycan cap epitope group (c13C6 competitors), 10 mAbs targeted the GP base (KZ52 competitors), another 10 were directed against the a-helical heptad repeat 2 in the GP2 ''stalk'' (HR2 epitope group, ADI-15974 competitors), and one mAb belonged to an undefined but GP1-specific epitope group (Bornholdt et al., 2016b) .
We assayed the 37 cross-reactive mAbs for their capacity to inhibit infection by rVSV particles bearing SUDV GP, the most divergent from EBOV GP in amino acid sequence. Neutralization potency was first evaluated at two concentrations, and mAbs advanced if >50% reduction in infection was observed at the higher dose ( Figures S1C-S1F ). Only 10 of 37 crossreactive mAbs showed significant neutralizing activity against rVSV-SUDV GP. Six of these NAbs belonged to the KZ52 competition group and targeted the GP base, whereas the remaining four were equally divided between the HR2 and 13C6 epitope groups (Figures 1A and S1C-S1F). These and previous results suggest that a small subset of crossreactive and cross-neutralizing antibodies is generated by the human immune response in the course of natural ebolavirus infection.
Analysis of mAb Neutralization Breadth In Vitro
To evaluate the breadth and potency of neutralization by the top ten NAbs identified above, we performed dose-response neutralization assays with rVSVs bearing GPs from all five known ebolaviruses-EBOV, BDBV, SUDV, Reston virus (RESTV), and Taï Forest virus (TAFV) (Figures 1B-1P ; Table S1 ). The HR2 binder, ADI-16061, potently neutralized infection by rVSVs bearing EBOV, BDBV, and TAFV GP with half-maximal inhibitory concentration (IC 50 ) values below 5 nM but had little activity against those bearing SUDV and RESTV GP. The second NAb from this group, ADI-15975, possessed an even narrower antiviral spectrum, with strong activity only against rVSV-EBOV GP ( Figures 1B, 1E , 1H, 1K, and 1N; Table S1 ).
The glycan cap binders, ADI-15750 and ADI-15968, neutralized rVSVs bearing EBOV, TAFV, and SUDV GP, albeit with weaker activity against SUDV GP ( Figures 1C, 1I, 1L ; Table  S1 ). Further, ADI-15750 was effective at neutralizing rVSV-RESTV GP but not rVSV-BDBV GP, whereas the converse was true for ADI-15968 (Figures 1F and 1O; Table S1 ). Thus, none of the mAbs directed against the GP stalk or glycan cap demonstrated pan-ebolavirus neutralizing profiles, consistent with the limited antigenic conservation across these GP surfaces (Figures 4, S3A, and S3B) .
Two NAbs recognizing the GP base, ADI-15878 and ADI-15742, possessed exceptionally broad and potent neutralizing activity (IC 50 <2 nM) against all five rVSV-GPs ( Figures 1D, 1G , 1J, 1M, and1P; Table S1 ). A third base-binding NAb, ADI-15946, potently neutralized EBOV, BDBV, and TAFV, but showed reduced or no activity toward rVSVs bearing SUDV and RESTV GP, respectively ( Figures 1D, 1G , 1J, 1M, and 1P; Table S1 ). The remaining three NAbs in this epitope class were not pursued further due to their limited neutralization breadth.
We advanced the broadest and most potent neutralizers in each epitope group for testing against authentic ebolaviruses (Figure 2) . The results largely corroborated our findings with rVSV-GPs and confirmed that only the base binders ADI-15878 and ADI-15742 could potently neutralize infection by EBOV, BDBV, and SUDV (IC 50 %1 nM) (Figure 2 ). However, the activity of these broadly neutralizing Abs (bNAbs) did not extend to the more divergent GPs of Lloviu virus (LLOV) and MARV (Table S1 ). These findings underscore the challenges inherent in achieving pan-filovirus or even pan-ebolavirus neutralization with single mAbs targeting surface-exposed GP epitopes.
Mapping of bNAb Epitopes Using Negative-Stain Electron Microscopy and Escape Mutant Analysis
To visualize each GP:bNAb complex, we performed negativestain transmission electron microscopy (EM) studies of the antigen binding fragments (Fabs) of ADI-16061, ADI-15750, ADI-15878, ADI-15742, and ADI-15946 bound to trimeric soluble EBOV GP (GPDTM). 3D reconstructions determined from the EM class averages confirmed previous epitope group assignments based on binding competition experiments (Bornholdt et al., 2016b) . To approximate bNAb footprints on GP, we fit the recently solved unliganded EBOV GPDTM X-ray crystal structure (PDB: 5JQ3) (Zhao et al., 2016) into the GP envelope obtained by image reconstruction (Figure 3) . Further, to identify GP residues critical for bNAb binding and viral neutralization, we selected neutralization escape mutants (Figures 3, S2 , and S3). rVSVGPs were serially passaged in the presence of each bNAb until (A) Heatmap of rVSV-SUDV GP neutralization activity by cross-reactive mAbs from a human EVD survivor mAb library. Activity at 330 nM (top) and 33 nM (bottom) of mAb is shown. mAbs with activity at both concentrations are highlighted in red. Unk., unknown competition group. See also Figure S1 . (B-P) Neutralization of rVSV-GPs by mAbs with SUDV GP-specific neutralizing activity in (A). Means ± SD for three replicates are shown. See also Table S1 .
complete viral resistance was observed, and the GP genes of viral clones were sequenced to identify escape mutations (Figures 3, S2, and S3) .
ADI-16061 bound to HR2 and an N-terminal portion of the membrane proximal external region (MPER) between residues 621-640 in the GP2 stalk, with an angle of approach perpendicular to the GP stalk and parallel to the viral membrane (Figure 3A) . Despite the compact nature of the GP stalk, three Fabs could bind per GP trimer, each rotated by $50 with respect to the GP 3-fold symmetry axis. Two independent mutations in HR2, H628N and D632E ( Figure 3E ), greatly reduced GP:bNAb binding ( Figure S2A ) and afforded escape from viral neutralization ( Figure S2B ). While residue H628 was visualized in the EBOV GP X-ray crystal structure (Zhao et al., 2016) , the complete ADI-16061 epitope likely extends past the last resolved amino acid residue (631), inclusive of D632E, and into the MPER (EBOV GP residues z633-657). The high degree of viral species-dependent sequence variation in the MPER probably accounts for the failure of ADI-16061 to neutralize RESTV and SUDV (Figures 1,  2 , and S3A).
Complexes between ADI-15750 and GPDTM were not amenable to 3D reconstruction due to partial mAb occupancy, likely resulting from poor binding affinity (data not shown). However, 2D class averages of these complexes showed the Fabs binding GP axially to the viral membrane, reminiscent of the binding modes of c13C6 and other glycan cap binders (Bornholdt et al., 2016b; Murin et al., 2014; Pallesen et al., 2016) (Figure S4A) . rVSV-EBOV GP particles escaped ADI-15750 neutralization via mutation of multiple glycan cap residues that compromised GP:bNAb binding to varying degrees ( Figures  S2, S3 , and S4). The ADI-15750 binding footprint inferred from the escape mutant analysis appears to overlap that of mAb c13C6 (Pallesen et al., 2016) (Figures 4D, 4E , S3, and S4).
Concordantly, binding of both mAbs was sensitive to the G271R escape mutation engendered by ADI-15750 ( Figures S4C  and S4D ).
The GP base-binding bNAbs ADI-15878 and ADI-15742 are clonal siblings with 90% and 95% identity in their variable heavy (V H ) and variable light (V L ) amino acid sequences, respectively (Bornholdt et al., 2016b) (Figure 6A) . Their Fabs showed a steep angle of approach similar to the SUDV-monospecific Fab 16F6 (Dias et al., 2011 ) but appeared to be rotated by z90 about their long axes relative to the EBOV-monospecific Fab KZ52 ( Figures  3B, 3C , and 3I) (Lee et al., 2008b) . The epitope targeted by ADI-15878 and ADI-15742 is also rotated by z60 about the GP 3-fold symmetry axis relative to the base binders KZ52, 16F6, c2G4, and c4G7 (Dias et al., 2011; Lee et al., 2008a; Murin et al., 2014; Pallesen et al., 2016) (Figures 3B, 3C , 3I, and 4). The ADI-15878/15742 footprint on GP comprises discontinuous sequences in both GP1 and GP2 subunits that span neighboring protomers, including putative membrane-seeking residues in the highly conserved GP2 internal fusion loop (IFL) ( Figures 3B, 3C , and 4). Consistent with a critical role for bNAb:IFL contacts, a single IFL point mutation, G528E, abolished both viral recognition and neutralization without observable effects on viral entry ( Figures 3F, 3G , S2, and S3). Both ADI-15742 and ADI-15878, like another base-binding NAb mAb-100, are also predicted to contact the complex N-liked glycan at GP2 residue 563, in the a-helical heptad repeat 1 (HR1) sequence of the adjacent protomer ( Figures 3B, 3C , 3F, 3G, and 4B) (Misasi et al., 2016) . Glycosylation of this residue is strictly conserved across all filovirus GPs ( Figure S3 ).
Unexpectedly, ADI-15878/15742 displayed enhanced binding and neutralization of rVSV-EBOV GP particles bearing the N563A mutation, indicating that the glycan on this residue impairs GP recognition. By contrast, removal of the N563 glycan abolished mAb-100 neutralization and modestly reduced the activity of the other base binders tested ( Figures 5D, S5D , S5E, and S5F). ADI-15946, the third base-binding bNAb identified herein, targets an epitope that is similarly positioned to those of mAbs KZ52, c2G4, and c4G7 (Lee et al., 2008a; Murin et al., 2014; Pallesen et al., 2016) but shifted upward toward the glycan cap . ADI-15946's angle of approach is similar to that of mAb c2G4 (Murin et al., 2014; Pallesen et al., 2016) and its contacts involve discontinuous sequences with a single GP protomer: GP1 base (residues 71-77), glycan cap (residues 251-303), and GP2 (residues 508-514) (Figures 3D and 4F) . A single amino acid change (K510E), adjacent to the KZ52/c2G4/ c4G7 escape mutation (Q508R) (Audet et al., 2014) , afforded complete viral resistance to ADI-15946 binding and neutralization ( Figures 3D, 3H , S2, and S3). A second mutation at a buried position in the GP1 base (E100K) weakened viral neutralization but did not substantially diminish ADI-15946:GP binding. The higher level of sequence conservation in the putative ADI-15946 epitope relative to those of c2G4, C4G7, and KZ52 likely explains the former's enhanced antiviral breadth (Figures 4F and S3D) . However, the greater sequence divergence of SUDV and RESTV GP at the proposed sites of contact (Figure S3 ) is consistent with the failure of ADI-15946 to neutralize viruses bearing these GPs.
Mechanisms of Antiviral Neutralization
The filovirus cell entry pathway is a complex, multistep process that culminates in GP-catalyzed fusion between viral and host endosomal membranes and escape of a viral nucleocapsid payload into the cytoplasm (reviewed in Miller and Chandran, 2012; Moller-Tank and Maury, 2015) . Following their attachment to the plasma membrane of a permissive cell, virions are internalized and trafficked to late endo/lysosomal compartments (Simmons et al., 2015; Spence et al., 2016) . In endosomes, resident host cysteine cathepsins cleave GP to remove the mucin and glycan cap sequences (Chandran et al., 2005; Schornberg et al., 2006) , thereby unmasking a binding site for the critical endosomal receptor, Niemann-Pick C1 (NPC1) (Bornholdt et al., 2016a; Carette et al., 2011; Cô té et al., 2011; Miller et al., 2012) . Recognition of NPC1 by a cleaved GP species (hereafter, GP CL ), together with one or more unknown host signals, is proposed to trigger GP refolding and the membrane fusion reaction that is coupled to it (Brecher et al., 2012; Miller et al., 2012; Spence et al., 2016; Wong et al., 2010) .
In initial studies, we found that ADI-15878, ADI-15742, and ADI-15946 were efficiently co-internalized with viral particles and delivered to NPC1 + late endosomes (Figures S5A and S5B for ADI-15878). Because GP CL :NPC1 recognition is an indispensable requirement for filovirus entry (Miller et al., 2012) , we first examined the capacity of the GP base-binding bNAbs to inhibit it in a competitive ELISA ( Figure 5A ). Pre-incubation of each bNAb with VSV particles bearing EBOV GP CL had no effect on viral capture of a soluble fragment of NPC1, whereas the mAbs MR72 and FVM04, which bind directly to the receptor- binding site (RBS) in GP CL , blocked NPC1 capture, as described previously (Bornholdt et al., 2016a; Howell et al., 2016) . Thus, consistent with their RBSdistal epitopes, none of the GP base binders described herein exert their antiviral effect by directly preventing the virus-receptor interaction. (Figures 3  and 4 ). Endosomal GP / GP CL cleavage is a prerequisite for GP CL :NPC1 binding and therefore essential for filovirus entry. Accordingly, we investigated if any of the NAbs could interfere with this proteolytic processing step, as reported for the human EBOV-specific GP base binders, KZ52 and mAb-100 (Misasi et al., 2016; Shedlock et al., 2010) . rVSV-EBOV GP particles were pre-incubated with each NAb and then exposed to the endosomal cysteine protease cathepsin L (CatL). GP cleavage was assessed by measuring exposure of the GP CL RBS with an NPC1-binding ELISA (Figure 5B) or by gel electrophoresis and immunoblotting ( Figure 5C ) as described (Chandran et al., 2005; Miller et al., 2012) . ADI-15946, similar to c2G4, c4G7, KZ52, and mAb-100, could inhibit GP / GP CL cleavage and GP CL RBS exposure in a dose-dependent manner. By contrast, ADI-15878 and ADI-15742 were ineffective at blocking GP / GP CL cleavage. These results are consistent with the proximity of the binding footprints of mAb-100, c2G4, c4G7, and ADI-15946 to the GP1 b13-b14 loop, which is proposed to be the initial target of proteolytic cleavage (Chandran et al., 2005; Dube et al., 2009; Lee et al., 2008a; Zhao et al., 2016) . ADI-15878 and ADI-15742 appear to bind distal to the b13-b14 loop ( Figures 3B-3D and 3I) .
The preceding findings suggested that ADI-15878 and ADI-15742 act primarily at a step that follows GP / GP CL cleavage and receptor engagement. Because an endosomally generated GP CL species (alone or in complex with NPC1) is the presumptive final target of these bNAbs, we examined the capacities of the base binders to neutralize VSV particles bearing GP CL generated with CatL ( Figures 5D, S5C , and S5G). Strikingly, GP cleavage enhanced the antiviral potencies of ADI-15946, ADI-15878, and ADI-15742 by 50-to 200-fold (not shown for ADI-15742), whereas it attenuated or eliminated neutralization by the other base binders tested.
Kinetic binding studies by biolayer interferometry (BLI) further elucidated pH-and cleavage-dependent changes in the apparent GP binding affinity of some NAbs ( Figure 5E ; Table S2 ). ADI-15878 bound with picomolar affinity to uncleaved GPDTM at pH 7.5, but suffered a striking (10 3 -to 10 4 -fold) loss in apparent binding affinity at pH 5.5, the approximate pH of late endosomes. However, it regained picomolar binding affinity for CatL-cleaved 
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The predicted GP:NAb contact surface is indicated as a yellow outline on a surface-shaded representation of the GPDTM trimer model (PDB: 5JQ3). Each amino acid residue in GP1 (blue) and GP2 (red) is shaded according to the degree of sequence conservation among ebolavirus GP proteins at that position, based on a multiple sequence alignment (light to dark, 0% to 100% sequence identity) (see the STAR Methods for details). In (A)-(C), the N-linked glycan on GP2 residue Asn 563 is indicated as a translucent envelope and green balls-and-sticks. Antibody contact sites in (C), (E), (G), and (H) are derived from published structures of EBOV GP:Fab complexes.
GP CL . ADI-15946 recognized uncleaved GPDTM with nanomolar affinity at pH 7.5 and 5.5 and also gained picomolar binding to GP CL at pH 5.5 (10 3 -to 10 4 -fold enhancement). Thus, the enhanced neutralization potential of these bNAbs against cleaved viruses may be at least partially attributable to improvements in GP binding. Interestingly, the monospecific base binders KZ52, c2G4, and c4G7 retained efficient binding to GP CL despite their loss of neutralization against cleaved viruses, indicating that the nature of the epitope recognized, and not only binding affinity, dictates the molecular mechanism by which GP base-binding NAbs block ebolavirus entry.
Together, these results suggest that the bNAbs ADI-15878 and ADI-15742 differ from previously described monospecific base binders like KZ52, c2G4, c4G7, and mAb-100, in their capacity to target and neutralize a cleaved GP species that is generated deep in the endocytic pathway ( Figure 5F ). Conversely, the latter NAbs appear to act principally at and/or prior to the GP / GP CL cleavage step. ADI-15946 displayed a dual behavior and may act both upstream, to block GP cleavage, and downstream, to target one or more GP CL -like species at or near the membrane fusion step.
Germline Origin of ADI-15878 and ADI-15742 and Sequence Determinants of Their Neutralization Potency and Breadth
To begin to define the molecular basis of broad neutralization by ADI-15878 and ADI-15742, we assigned the V H and V L sequences of each bNAb to their respective germline genes and reverted ADI-15878 to its nearest inferred germline (IGL) precursor (Figure 6A) . ADI-15878 IGL was engineered to contain germline reversions in most framework and complementaritydetermining regions (CDR) segments but retain wild-type (WT) (fully mature) CDR-H3, because the originating germline sequence in this region could not be predicted with confidence given the highly diverse nature of D segments upon VDJ recombination. EBOV GP with single-digit nanomolar affinity (20-to 100-fold lower K D app ), but picomolar affinity to EBOV GP required pairing of both mature chains ( Figures S6A and S6C) . The higher affinity of mature variable domains for binding to EBOV GP was primarily due to slower dissociation rates (k off ) relative to variants containing one or both IGL segments. These changes in binding affinity associated with variable region maturation were accompanied by incremental improvements in neutralization potency and breadth. However, neutralization of rVSVs bearing SUDV and RESTV GP was especially dependent on sequences containing light chain SHMs, indicating a critical role for ADI-15878 light chain:GP interactions in neutralization breadth ( Figures 6C and S7 ). Together, these findings suggest that the CDRs of both V H (non-CDR-H3) and V L sequences of ADI-15878 and ADI-15742 make key contributions to the energetics of ebolavirus GP binding and to pan-ebolavirus neutralizing efficacy. To complement the above analysis, we separately assessed the contributions of individual CDR-H3 residues in ADI-15878 by alanine scanning mutagenesis ( Figures 6B, 6C , S6, and S7). WT ADI-15878 mAb exhibited a slow off rate for both GP and GP CL (below the 10 À7 s À1 detection limit of BLI, providing a <1
pM estimate of K D app ). Most of the WT / Ala CDR-H3 mutants exhibited dramatically lower binding to EBOV GP (K D app s 20-to 74,000-fold higher than 1 pM), indicating that mutations were either detrimental to direct binding interactions or altered productive CDR-H3 loop conformations. However, all of the WT / Ala CDR-H3 mutants had only modest effects on neutralization potency against rVSV-EBOV GP relative to WT ADI-15878, except D95A and W99A, which suffered an z99% reduction in potency. The impact on neutralization of each CDR-H3 mutant, including D95A and W99A, was even less pronounced against rVSV-EBOV GP CL ( Figures 6C and S7) , consistent with enhanced mAb:GP CL binding affinity and GP CL neutralization sensitivity ( Figure 6B ; Table S2 ). These neutralization trends extended to GPs from the other ebolaviruses, except for Y100 c A, which was selectively less potent against rVSVs bearing SUDV GP and GP CL ( Figures 6C, S7C, and S7D) . These results suggest that interactions between the CDR-H3 loop of ADI-15878 and structurally conserved elements in the GP2 IFL and HR1 contribute to pan-ebolavirus recognition and neutralization. Furthermore, they identify three WT side chains (D95, W99, Y100 c ) that are critical to the pan-ebolavirus neutralizing activity of ADI-15878.
Protective Efficacy in Animal Models of EBOV, SUDV, and BDBV Challenge
We assessed the protective efficacy of the human bNAbs in three small-animal models of lethal ebolavirus challenge (Figure 7) . First, wild-type (WT) BALB/c mice were exposed to mouse-adapted EBOV (EBOV-MA) and then administered a single dose of each bNAb at 2 days post-infection ( Figures 7A and  7B ). bNAbs from each epitope group were highly (R80%) protective against EBOV in this stringent post-exposure setting with little or no weight loss apparent in antibody-treated animals. We next evaluated the bNAbs in the type I interferon a/b receptor-deficient mouse model for SUDV challenge ( Figures 7C and  7D ) (Brannan et al., 2015) . Mice were exposed to WT SUDV and then dosed with each bNAb on days 1 and 4 post-infection. ADI-15878 and ADI-15742 afforded R95% survival and greatly reduced weight loss, relative to the PBS vehicle group. By contrast, ADI-16061 and ADI-15946, both weak SUDV neutralizers, provided little or no protection. To the contrary, ADI-16061 significantly increased mortality in two independent experiments (p < 0.05), raising the possibility that it can enhance SUDV infection in vivo.
Finally, we tested the anti-BDBV efficacy of the two pan-ebolavirus bNAbs, ADI-15878 and ADI-15742, in the domestic ferret, which is the only described non-NHP model for BDBV challenge ( Figures 7E and 7F) Table S3 . n, number of animals per group. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. All other comparisons to the PBS group were not significant.
Animals received two doses of each bNAb. As observed previously (Cross et al., 2016; Kozak et al., 2016) , BDBV infection was uniformly lethal, with PBStreated animals succumbing between days 8-10 following challenge. By contrast, both bNAbs afforded highly significant levels of survival (p < 0.01; three of four animals for ADI-15878; two of four for ADI-15742). Furthermore, peak viremia levels correlated with bNAb treatment and survival outcome, with lower viral titers observed in the surviving animals relative to those that succumbed to infection (p = 0.0011) and in bNAb-treated animals relative to PBS-treated controls (p = 0.0006). Viremia also trended lower in animals receiving ADI-15878 relative to those receiving ADI-15742, but this difference did not reach statistical significance. Strikingly, analysis of the BDBV GP consensus sequence in blood samples collected from viremic animals at day 6 postchallenge revealed a single nucleotide change encoding the G528S mutation in all four of the ADI-15742-treated animals, but in none of the ADI-15878-treated and PBS-treated animals for which viral RNA could be isolated (Table S3 ). Mutation of the same GP2 IFL residue conferred viral neutralization escape from both antibodies in tissue culture (Figures 3, S2 , and S3). These results raise the possibility that ADI-15878 engenders viral neutralization escape to a lesser extent than ADI-15742 in vivo and suggests that ADI-15878 should be prioritized over ADI-15742 as a component of a pan-ebolavirus immunotherapeutic.
In sum, our findings demonstrate that the pan-ebolavirus bNAbs ADI-15878 and ADI-15742 can afford post-exposure protection against challenge by the three divergent ebolaviruses currently associated with lethal disease outbreaks in humans.
DISCUSSION
Herein, we identified bNAbs from a human survivor of the 2013-2016 West African EBOV epidemic, including two with potent pan-ebolavirus neutralizing activity. Flyak et al. (2016) previously reported a bNAb, BDBV43, from a survivor of BDBV infection, but two features limit its therapeutic utility in comparison to the human bNAbs described in this study. First, BDBV43 neutralizes EBOV, BDBV, and SUDV weakly (IC 50 >100 nM). Second, BDBV43, a glycan cap binder, cross-reacts with the secreted form of the glycoprotein (sGP). sGP is present at high levels in EVD patients (Sanchez et al., 1996) and may ''soak up'' mAbs that recognize it (Mohan et al., 2012) potentially reducing their capacity to target and neutralize infectious virions.
We uncovered cross-neutralizing mAbs that not only target the glycan cap and sGP (ADI-15750) (Bornholdt et al., 2016b) but also other structural regions of the trimeric GP spike, namely the base and internal fusion loop (IFL) (ADI-15878, ADI-15742, ADI-15946) and the stalk (ADI-16061). The broadest and most potent of these bNAbs recognize base epitopes. ADI-15878 and ADI-15742, two clonally related mAbs of the 349 screened, afforded highly potent neutralizing activity (IC 50 <1 nM) against all five known ebolaviruses. A third base binder, ADI-15946, could potently neutralize four of five ebolaviruses (except RESTV) but demonstrated only modest activity against SUDV.
Our findings reveal unusual modes of neutralization by ADI-15878, ADI-15742, and ADI-15946. Specifically, ADI-15878 and ADI-15742 appear to target a cleaved GP intermediate in endosomes, whereas the prototypic base binders KZ52, c2G4, and c4G7 act only at one or more upstream steps in entry, as also proposed by Misasi et al. (2016) (Figures 5F, S5A , and S5B). The protomer-spanning mode of ADI-15878/15742 binding is predicted to ''lock'' the cleaved GP trimer, whether free or bound to NPC1, in a pre-fusion state, thereby arresting GP conformational changes required for viral membrane fusion. ADI-15946 appears to act at both upstream and downstream entry steps and may arrest the transduction of receptor-induced conformational changes required for fusion by binding GP1 residues adjacent to the RBS (71-77) ( Figures 4F and S3D) . These residues were shown to rearrange upon GP CL :NPC1 association (Wang et al., 2016) . The prototypic base binders do not appear to make such GP1 contacts ( Figures 4G and 4H) .
To explore the genesis of pan-ebolavirus bNAbs in humans infected with a single ebolavirus, we characterized ''germline-reverted'' variants of ADI-15878 for viral binding and neutralization. Our results suggest that, although ADI-15878/15742-like panebolavirus neutralizing mAbs did not arise with high frequency in this human survivor of EVD (2/349), the barrier for maturation of such mAbs may be lower than that seen in some other viral diseases. ADI-15878 and ADI-15742 originate from the most common germline heavy chain segment (VH3-23), do not possess extremely long CDR-H3s (15 amino acids versus 20-33 for HIV-1-specific bNAbs whose epitopes contain protein sequences and glycans), and require only a few SHMs for broad and potent antiviral activity (z6% amino acid changes in V H versus z30% for HIV-1 CD4-binding site-specific bNAbs) (Bornholdt et al., 2016b; Corti and Lanzavecchia, 2013; Tiller et al., 2013) . Furthermore, a germline-reverted variant of ADI-15878 (albeit with a mature CDR-H3) could recognize EBOV GP with submicromolar affinity (Figures 6 and S6) . The presence of bNAbs in polyclonal primary responses to ebolavirus infection contrasts with the origin of such bNAbs in human subjects who control long-term HIV-1 infection or with active secondary dengue virus infection (Corti and Lanzavecchia, 2013; Dejnirattisai et al., 2015) .
Our findings further suggest the possibility of eliciting antiebolavirus bNAbs efficiently in humans through immunization with a suitably engineered immunogen, because the sites of broad vulnerability within GP are clearly defined, and the generation of ADI-15878-like responses requires only subtle maturation of an abundantly represented germline. Strikingly, the germline-reverted ADI-15878 variant could bind to soluble EBOV GP CL with single-digit nanomolar K D app and neutralize viruses bearing EBOV and SUDV GP CL ( Figures 6C, S6A, and S7A) . Thus, minimized EBOV GP constructs mimicking GP CL may preferentially elicit ADI-15878-like antibodies through enhanced presentation of vulnerable IFL epitopes, increased activation of the appropriate B cell precursors, and removal of putatively immunodominant and generally non-neutralizing epitopes in the glycan cap and mucin domain. Such germline-targeting immunogens could be further improved by modification of the GP glycan landscape (e.g., at residue 563) and may have utility as part of a broadly protective next-generation filovirus vaccine.
ADI-15878 and ADI-15742 protect against EBOV, BDBV, and SUDV in vivo under stringent post-exposure conditions when administered as monotherapy, and our results suggest that they should also afford protection against all other known ebolaviruses. By contrast, the ZMapp cocktail, which represents the current state-of-the-art for anti-filovirus immunotherapy, is only efficacious against a single virus, EBOV. Moreover, ZMapp component c13C6 cross-reacts with sGP, and all three mAbs lack activity against endosomally cleaved forms of GP. Nextgeneration cocktails comprising bNAbs like ADI-15878, ADI-15946, and/or CA45 (Zhao et al., 2017 ; this issue of Cell), which elude subversion by sGP (Bornholdt et al., 2016b) and can act synergistically to block both uncleaved and cleaved forms of GP (Figure 5F ), should provide broad protection at significantly lower doses, while reducing the risk of neutralization escape that is inherent to antibody monotherapy.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Vero female African grivet monkey cells, HEK293T female human embryonic kidney fibroblast cells, and U2OS female human osteosarcoma cells were obtained from the American Type Culture Collection (ATCC). Vero and HEK293T cells were cultured in high-glucose Dulbecco's modified Eagle medium (DMEM; Thermo Fisher) supplemented with 10% fetal bovine serum (Atlanta Biologicals), 1% GlutaMAX (Thermo Fisher), and 1% penicillin-streptomycin (Thermo Fisher). U2OS cells were cultured in McCoy's-5A medium (Thermo Fisher) with serum and additives as above. Suspension-adapted 293-Freestyle (293-F) cells were obtained from Thermo Fisher, and cultivated in Freestyle 293 serum-free expression medium (Thermo Fisher). Cell lines were maintained in a humidified 37 C incubator supplied with 5% CO2 (Vero, HEK293T) or 8% CO2 (293-F). Cell lines were not authenticated following purchase.
Vesicular stomatitis virus (VSV) recombinants and pseudotypes
Recombinant vesicular stomatitis Indiana viruses (rVSV) expressing eGFP in the first position, and encoding representative GP proteins from EBOV/Mayinga (EBOV/H.sap-tc/COD/76/Yambuku-Mayinga), EBOV/Makona (EBOV/H.sap-rec/LBR/14/Makona-L2014), BDBV (BDBV/H.sap/UGA/07/But-811250), SUDV/Boneface (SUDV/C.por-lab/SSD/76/Boneface), RESTV (RESTV/M.fastc/USA/89/Phi89-AZ-1435), and LLOV (LLOV/M.sch-wt/ESP/03/Asturias-Bat86), in place of VSV G have been described previously (Ng et al., 2014; Wec et al., 2016; Wong et al., 2010) . VSV pseudotypes bearing eGFP and GP proteins from TAFV (TAFV/H.sap-tc/ CIV/94/CDC807212) and MARV (MARV/H.sap-tc/KEN/80/Mt. Elgon-Musoke) were generated as described (Takada et al., 1997) .
Authentic filoviruses
The authentic filoviruses EBOV/''Zaire 1995'' (EBOV/H.sap-tc/COD/95/Kik-9510621) , mouse-adapted EBOV/ Mayinga (EBOV-MA) (Bray et al., 1998) , SUDV/Boneface-USAMRIID111808 (WHO International Study Team, 1978) , and BDBV/ 200706291 (Towner et al., 2008) were used in this study.
METHOD DETAILS
Generation of cleaved VSV-GP particles and GPDTM ectodomain proteins In some experiments, cleaved viral particles bearing GP CL were first generated by incubation with thermolysin (200 mg/mL, pH 7.5, 37
C for 1 h; Sigma-Aldrich) or recombinant human cathepsin L (CatL, 2 ng/mL, pH 5.5, 37 C for 1 h; R&D Systems), as described previously . Reactions were stopped by removal onto ice and addition of phosphoramidon (1 mM) or E-64 (10 mM), respectively, and viral particles were used immediately for infectivity assays. A recombinant, soluble GPDTM protein (Bornholdt et al., 2016b) was also cleaved essentially as described above.
VSV infectivity measurements and neutralization assays Viral infectivities were measured by automated counting of eGFP+ cells (infectious units; IU) using a CellInsight CX5 imager (Thermo Fisher) at 12-14 hr post-infection. For mAb neutralization experiments, pre-titrated amounts of VSV-GP particles (MOI z1 IU per cell) were incubated with increasing concentrations of test mAb at room temp for 1 hr, and then added to confluent cell monolayers in 96-well plates. Viral neutralization data were subjected to nonlinear regression analysis to derive EC 50 values (4-parameter, variable slope sigmoidal dose-response equation; GraphPad Prism).
Authentic filovirus microneutralization assays
Antibodies were diluted to indicated concentrations in culture media and incubated with virus for 1 hr. Vero E6 cells were exposed to antibody/virus inoculum at an MOI of 0.2 (EBOV, BDBV) or 0.5 (SUDV) plaque-forming unit (PFU)/cell for 1 hr. Antibody/virus inoculum was then removed and fresh culture media was added. At 48 hr post-infection, cells were fixed, and infected cells were immunostained using the antibodies KZ52, ADI-15878, and 3C10 for EBOV, BDBV, and SUDV and quantitated by automated fluorescence microscopy, as described .
Generation of mAbs
Antibodies used for initial binding and neutralization screening, as well as germline-reverted (IGL) mAb constructs and WT:IGL chimeras of ADI-15878, were expressed in Saccharomyces cerevisiae as described previously (Bornholdt et al., 2016b) . Briefly, yeast cultures were grown in 24-well plates, harvested by centrifugation after 6 days, and IgGs were purified by protein A-affinity chromatography. IgGs used in in vivo challenge experiments were expressed in FreeStyle TM 293-F cells by transient co-transfection of heavy and light chain plasmids (ThermoFisher). One day prior to transfection, HEK293 cells were passaged at 2.0-2.5 3 10 6 cells per ml. On the day of transfection, cells were pelleted by centrifuging at 400 3g for 5 min, and cell pellets were resuspended in fresh FreeStyle F17 medium at a density of 4 3 10 6 cell per ml and returned to the incubator. A transfection mixture was prepared by first diluting the plasmid DNA preparations in FreeStyle F17 medium (1.33 mg total plasmid DNA per ml of culture). Transfection agent, PEIpro (Polyplus Transfection, Illkirch, France), was then added to the diluted DNA at a DNA-to-PEI ratio of 1:2, and the mixture was incubated at room temperature for 10 min. The transfection mixture was then added to the culture. Cultures were harvested six days post transfection by two rounds of centrifugation, each at 2000 3g for 5 min, and antibodies were purified the clarified conditioned medium by passing over Protein A agarose (MabSelect SuRe from GE Healthcare Life Sciences). The bound antibodies were washed with PBS, eluted with 200 mM acetic acid[pH 3.5],50 mM NaCl into 1/8 th volume 2M
HEPES[pH 8.0], and buffer-exchanged into PBS. Fabs were generated by digesting the IgGs with papain for 2 hr at 30 C. Reactions were terminated by the addition of iodoacetamide, and the Fab and Fc mixtures were passed over Protein A agarose to remove Fc fragments and undigested IgG. The flowthrough was then passed over CaptureSelect IgG-CH1 affinity resin (ThermoFisher), and eluted and buffer-exchanged as above.
ELISAs for GP:mAb binding
To identify GP cross-reactive mAbs in Figures 1 and S1 , normalized amounts of rVSVs bearing EBOV, BDBV, and SUDV GP were coated onto plates at 4 C. Plates were then blocked with PBS containing 3% bovine serum albumin (PBSA), and incubated with dilutions of test antibody (5, 50 nM). Bound Abs were detected with anti-human IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology) and Ultra-TMB colorimetric substrate (Thermo Fisher). All incubations were performed for 1 hr at 37 C.
Competition ELISAs for GP/mAb binding to NPC1
The viral lipid envelopes of rVSV-EBOV GP particles were labeled with biotin using a function-spacer-lipid construct (FSL-biotin) (Sigma-Aldrich) for 1 hr at pH 7.5 and 37 C, as described (Ng et al., 2014) . Biotinylated viral particles bearing GP CL were generated by incubation with thermolysin, and then captured onto high-binding 96-well ELISA plates precoated with recombinant streptavidin (0.65 mg/mL; Sigma-Aldrich). Plates were then blocked with PBSA, and incubated with serial dilutions of test mAbs. Washed plates were then incubated with a pre-titrated concentration of soluble, FLAG epitope-tagged, NPC1 domain C (NPC1-C) protein (Bornholdt et al., 2016a) , and bound NPC1-C was detected with an anti-FLAG antibody conjugated to horseradish peroxidase (Sigma-Aldrich). All incubations were performed for 1 hr at 37 C.
ELISAs and immunoblots to detect mAb inhibition of GP cleavage In Figure 5B , we used exposure of the NPC1-binding site in EBOV GP CL as a proxy for successful GP/GP CL cleavage by CatL. rVSV-EBOV GP particles, biotinylated as above, were preincubated with mixtures of test mAb and irrelevant human IgG (test mAb at 50, 250, or 1000 nM; 1000 nM total IgG per reaction) for 1 hr at pH 5.5 and 37 C. Reactions were then incubated with CatL (4 ng/mL and 37 C for 30 min). Reactions were then stopped with the cysteine cathepsin inhibitor E-64, readjusted to neutral pH with PBS, and captured onto streptavidin-coated ELISA plates. NPC1-C binding was measured as above.
Samples treated with the highest concentration of test mAb were also subjected to western blotting ( Figure 5C ). Cleaved GP1 species were detected by immunoblotting with h21D10 mAb (a gift from Dr. Javad Aman) directly conjugated to horseradish peroxidase.
Selection of viral neutralization escape mutants
Escape mutant selections were performed by serial passage of rVSV-GP particles in the presence of test mAb. Briefly, serial 3-fold dilutions of virus were preincubated with a concentration of mAb corresponding to the IC 90 value derived from neutralization assays, and then added to confluent monolayers of Vero cells in 12-well plates, in duplicate. Infection was allowed to proceed to completion e4 Cell 169, 878-890.e1-e6, May 18, 2017 BDBV GP sequencing from ferret blood samples Total RNA was extracted from ferret blood samples at 3, 6, 10, and 14 days post-challenge with the QIAamp Viral RNA Mini Kit (QIAGEN). RNA was reverse transcribed with SuperScript IV VILO Master Mix (Thermo Fisher) according to the manufacturer's instructions. PCR reaction conditions were as follows: 45 cycles of 95 C for 30 s, 55 C for 30 s, and 72 C for 60 s. PCR product purification from the agarose gel was performed with the NucleoSpin gel and PCR clean-up kit (Macherey-Nagel), and subjected to Sanger DNA sequencing. The sequences were aligned to that of the challenge virus preparation and the published BDBV GP sequence (Bundibugyo virus/H. sap-tc/UGA/2007/Bundibugyo-200706291; GenBank accession number KU182911.1). Sequencing primers are indicated in the Key Resources Table. Animal welfare statement Murine challenge studies were conducted under IACUC-approved protocols in compliance with the Animal Welfare Act, PHS Policy, and other applicable federal statutes and regulations relating to animals and experiments involving animals. The facility where these studies were conducted (USAMRIID) is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC) and adhere to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council (2011). The animal facility at USAMRIID performs routine clinical observations to evaluate anorexia, activity, dehydration and edema. Mice were observed daily by assigned Veterinary Medicine Division personnel for husbandry conditions, humane care and general health. All procedures for animal care and housing are in accordance with the NRC Guide for the Care and Use of Laboratory Animals (1996) (Clark et al., 1997) and the Animal Welfare Act as amended and standards incorporated in 9 CFR Part 3, 1991. For all mouse studies described, mice were purchased from commercial suppliers and housed in microisolator cages (10 mice per cage) with water and food provided ad libitum. Once received, mice were placed in quarantine and evaluated for the presence of parasites, infectious agents, or other conditions that could adversely affect the studies. At the end of the quarantine period an American College of Laboratory Animal Medicine (ACLAM)-certified veterinarian released the animals for use in studies once they were determined to be healthy. All mice used for the described studies were naive animals that had not previously been used for any other study or previously exposed to test antibodies or viruses.
Ferret challenge studies were approved by the Animal Care Committee (ACC) of the Canadian Science Centre for Human and Animal Health (CSCHAH) in Winnipeg, Canada, in accordance with guidelines from the Canadian Council on Animal Care (CCAC). Ferrets were obtained from Marshall BioResources USA, and were monitored daily for food and water consumption and given environmental enrichment according to the guidelines for the species. Cage cleaning and complete bedding exchange was carried out three times per week. Two or three animals were housed per cage in the Allentown caging system. Each unit is ventilated with a HEPA blower system and all units are manufactured from stainless steel and are autoclavable. Following viral challenge, survival, weight, temperature and overall health were monitored daily and recorded on the humane scoring chart. Ferretsused for BDBV challenges were previously involved in a non-interventional influenza A virus (IAV subtype H5N1) pathogenesis study. Thy were challenged with IAV, and did seroconvert by ELISA, but did not present with disease symptoms. No treatments or vaccinations were administered in that prior study. BDBV challenge was performed 40 days after the IAV infection, a period sufficient for immune recovery of the animals.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details of experiments, including numbers of replicates (n), measures of precision (standard deviation, SD), and the statistical test(s) used can be found in the figure legends, figures, and Results. Dose-response neutralization curves were fit to a logistic equation by nonlinear regression analysis. 95% confidence intervals (95% CI) for the extracted IC 50 parameter were estimated under the assumption of normality. Analysis of survival curves in Figure 7 was performed with the Mantel-Cox (log-rank) test. Statistical comparisons of viral titers in Figure 7F (also see Results) were carried out with a Mann-Whitney U test. Testing level (alpha) was 0.05 for all statistical tests. All analyses were carried out in GraphPad Prism.
DATA AND SOFTWARE AVAILABILITY
Sequences for all 349 mAbs from the Adimab collection (Bornholdt et al., 2016b) have been deposited in GenBank (see Table S3 for accession numbers). The accession numbers for the negative stain-EM reconstructions reported in this paper are Electron Microscopy Data Bank under accession numbers EMDB: EMD-8698-EMD-8701 (see Key Resources Table for details). Figure S1 . Screening a Collection of 349 Human EBOV Survivor mAbs for Pan-Ebolavirus Binders and Neutralizers, Related to Figure 1 (A) Capacity of mAbs to recognize rVSVs bearing EBOV, BDBV, and SUDV GP in an ELISA. A 450 , absorbance at 450 nm. Red line indicates ELISA reactivity threshold for selecting cross-reactive mAbs, equivalent to 33% of the positive control. (B) mAbs cross-reactive with SUDV GP in (A) were assayed for binding to rVSVs bearing EBOV, BDBV, and SUDV GP by ELISA. Means ± SD for three replicates are shown. Red line indicates ELISA reactivity threshold for selecting cross-reactive mAbs. (C-F) Capacity of cross-reactive mAbs to neutralize rVSV-SUDV GP infection at two mAb concentrations. Means ± standard deviation (SD) for three replicates are shown. Asterisks, infectivity below the detection limit. Red line indicates neutralization efficacy threshold for selecting cross-neutralizing mAbs. mAbs are binned by competition/epitope group.
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